Skip to main navigation Skip to search Skip to main content

OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study

  • Liam G Heaney
  • , Andrew Menzies-Gow
  • , Mark Gurnell
  • , Jonathan Corren
  • , Elisabeth H Bel
  • , Jorge F Maspero
  • , Timothy Harrison
  • , David Jackson
  • , David Price
  • , Njira Lugogo
  • , James Kreindler
  • , Annie Burden
  • , Alex de Giorgio-Miller
  • , Kelly Padilla
  • , Ubaldo J. Martin
  • , Esther Garcia Gil
  • Cambridge Biomedical Campus
  • David Geffen School of Medicine at UCLA and Allergy Medical Clinic Inc
  • University of Amsterdam
  • University of Nottingham
  • AstraZeneca
  • West London NHS Trust
  • Observational and Pragmatic Research Institute Singapore
  • University of Michigan, Ann Arbor
  • AstraZeneca, Wilmington
  • AstraZeneca, US
  • AstraZeneca, Gaithersburg
  • Queen's University Belfast
  • National Health Service
  • AstraZeneca, Barcelona

Research output: Contribution to journalAbstractpeer-review

27 Downloads (Pure)

Abstract

Severe asthma is frequently associated with comorbidities. Nasal polyps (NP), in particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced response to benralizumab in terms of asthma exacerbations and lung function. I
Original languageEnglish
Article numberA1355
Number of pages1
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume203
Early online date19 May 2021
DOIs
Publication statusPublished - 2021
EventATS International Conference Committee: ATS 2021 - Virtual event
Duration: 14 May 202119 May 2021
https://conference.thoracic.org/

Fingerprint

Dive into the research topics of 'OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study'. Together they form a unique fingerprint.

Cite this